✦ LIBER ✦

Development of a composite index for noncompliance patients in clinical trials

✍ Scribed by M. De Rosa; A. Pession; R. Rondelli; S. Rago

Book ID: 113297655
Publisher: Elsevier Science
Year: 1992
Tongue: English
Weight: 97 KB
Volume: 13
Category: Article
ISSN: 0197-2456
DOI: 10.1016/0197-2456(92)90184-2

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

201 Development of a Composite Endpoint

201 Development of a Composite Endpoint (CEP) for Clinical Trials on Immunosuppressants (IS) in Lung Transplantation

✍ C. Monchaud; B. Marin; M. Estenne; P. Marquet 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 79 KB

Capturing patients' perspectives of trea

Capturing patients' perspectives of treatment in clinical trials/drug development

✍ Asha Hareendran; Ari Gnanasakthy; Randall Winnette; Dennis Revicki 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 179 KB

Development of a composite endpoint for

Development of a composite endpoint for randomized controlled trials in liver surgery

✍ M. A. J. van den Broek; R. M. van Dam; G. J. P. van Breukelen; M. H. Bemelmans; 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 136 KB 👁 2 views

A Comparison of Methods for Estimating t

A Comparison of Methods for Estimating the Causal Effect of a Treatment in Randomized Clinical Trials Subject to Noncompliance

✍ Roderick J. Little; Qi Long; Xihong Lin 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 184 KB

Selecting Reliable Pharmacokinetic Data

Selecting Reliable Pharmacokinetic Data for Explanatory Analyses of Clinical Trials in the Presence of Possible Noncompliance

✍ Jianfeng Lu; Jean-Michel Gries; Davide Verotta; Lewis B. Sheiner 📂 Article 📅 2001 🏛 Springer 🌐 English ⚖ 203 KB

Development of responder definitions for

Development of responder definitions for fibromyalgia clinical trials

✍ Lesley M. Arnold; David A. Williams; James I. Hudson; Susan A. Martin; Daniel J. 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 156 KB

## Abstract ## Objective To develop responder definitions for fibromyalgia (FM) clinical trials using key symptom and function domains. ## Methods Twenty‐four candidate responder definitions were developed by expert consensus and were evaluated in 12 randomized, placebo‐controlled trials of 4 me